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Abstract
Background: In Gilles de la Tourette syndrome (GTS) an immunopathogenic influence of autoantibodies is suspected.
In familial GTS a disruption of the contactin-associated protein 2 gene (CNTNAP2), coding for the contactin-associated
protein 2 (CASPR2), has been reported. Autoantibodies against CASPR2 are associated with other movement disorders
like Morvan’s syndrome. In addition, positive oligoclonal bands (OCB) in cerebrospinal fluid (CSF) have been found in
more than a third of GTS patients, indicating a pathological intrathecal immunoglobulin synthesis. These findings drove
the hypothesis that CASPR2 antibodies are involved in GTS.
Methods: In this cross sectional study, 51 patients with GTS were examined for CASPR2 and other autoantibodies. We
used indirect immunofluorescence or enzyme-linked visualization in cell-based assays on tissue sections from cerebellum
(rat and monkey), hippocampus (rat), and immunoblots for the detection of specific or any other autoantibodies.
Results: Serum samples from 51 GTS patients, mean age 35.0 ± 13.1 y, were analyzed. In none of the 51 GTS sera
CASPR2 antibodies were detectable. Neither had we found any other specific autoantibodies (LGI1, NMDAR, AMPA1,
AMPA/2 or GABAB1/B2). An anti-nuclear pattern of immunoreactivity was observed in 7/51 (14 %) samples. In these
patients an immunoblot analysis was used to rule out antibodies directed against well-defined intracellular target
antigens. A specific anti-neuronal binding pattern could not be seen in any of the tissue sections.
Conclusions: The results negate that CASPR2 antibodies play a role in the pathogenesis of Tourette syndrome and do
not support the assumption that anti-neuronal antibodies are involved.
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Introduction
Gilles de la Tourette syndrome is a chronic neuro-
psychiatric disorder with an estimated prevalence rate of
about 0.6–1 % [1]. It is thought that pathophysiologically
both genetic vulnerability and environmental factors – in-
cluding immunological changes - are involved. Supporting
an immunopathogenic influence, elevated concentrations
of Tumor necrosis factor alpha (TNF-α) and Interleukin
12 (IL-12) have been detected in patients with GTS [2]. In
addition, positive oligoclonal bands in the cerebrospinal
fluid have been found in 38 % of GTS patients [3]. This
strongly suggests a pathological intrathecal immunoglobu-
lin synthesis in GTS, because positive OCBs are found in
only 3 % of the general population. However, the role of
autoantibodies in GTS remains unclear, since contradict-
ory results have been found [4].
In the last decade, several antibodies targeting neuronal
surface proteins (especially ion channels) have been identi-
fied to be causative in different neurological disorders in-
cluding idiopathic limbic encephalitis (LE) and Morvan’s
syndrome [5]. For example in LE AMPA receptor anti-
bodies (AMPA 1 and AMPA 2), which are directed against
the GluA1 and GluA2 subunits of AMPA receptors, can be
found. In Morvan’s syndrome, characterized by peripheral
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nerve hyperexcitability, an association with the contactin-
associated protein 2 (CASPR2) has been demonstrated [6].
Accordingly, clinical improvement following immuno-
therapy has been reported [7]. In addition, CASPR2 is a
known genetic risk factor of autism and has been sug-
gested to play a role in several other neurodevelopmen-
tal disorders including ADHD and OCD [8]. CASPR2,
expressed in juxtaparanodal regions of myelinated
axons prominently in the brain, is linked to voltage
gated potassium channels (VGKC) [9]. It is encoded by
the contactin-associated protein 2 gene (CNTNAP2).
Most interestingly, a disruption of the CNTNAP2 gene
by chromosome insertion has been found in a GTS
family in both the affected father and two affected
children. The authors speculated that the disruption
leads to a disturbed distribution of K+ channels causing
unwanted movements like tics [10]. So far, only one
other family - without GTS - has been described with a
disrupted CNTNAP2 gene [11]. This observation led to
the conclusion that not the disruption of the CNTNAP2
gene, but a dysfunction of the ion channel by CASPR2
antibodies might be causative in GTS. The aim of this
study was to investigate for the first time CASPR2 anti-
bodies in sera of a large group of adult patients with GTS.
Methods
In this study, we included 51 consecutive adult patients
with GTS according to DSM-IV-TR confirmed by one of
the authors (KMV). All patients were recruited from the
Tourette’s outpatient clinic at the Hannover Medical
School. Blood samples were collected after approval by
the ethics committee of the Hannover Medical School.
Patients with autoimmune diseases of the CNS were not
eligible to participate. All patients gave their written
informed consent before entering the study.
From each patient 7.5 mL blood were drawn, centri-
fuged at 3500 rpm for 15 min, and serum fresh frozen
at −80 °C. Within one year serum was tested for antibodies
using plasmid transfected HEK293 cells (Autoimmune-
Encephalitis-Mosaik1 CA 1439–2, Euroimmun, Lübeck,
Germany). The transfected cells ectopically expressed either
the CASPR2, the N-methyl-D-aspartic acid receptor
(NMDAR), the α-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid receptor (AMPAR), the Leucin-rich glioma
inactivated protein (LGI1), or the gamma-aminobutyric
acid receptor (GABAB1/B2). Patient serum was diluted
1:10 and incubated with the HEK cells on cover slides.
Bound antibodies were labelled with secondary goat anti-
human fluorescein-conjugated antibodies (Euroimmun,
Lübeck, Germany). Serum from CASPR2 and NMDAR
positive patients was used as positive control.
To allow detection of antibodies with an unknown
target antigen, biochip mosaics containing hippocampal
sections (rat), cerebellum (monkey), and non-transfected
EU90 cells (negative control) were used (IIF: Glutamate-
Receptor-Mosaic 3, FA Euroimmun, Lübeck, Germany).
These were incubated with diluted patient sera for
30 min, washed and labelled using fluorescein isothiocyan-
ate (FITC) anti-human IgG as secondary antibody. Fur-
thermore, diluted patient sera (1:10) were incubated with
tissue sections from cerebellum (monkey), washed with
secondary anti-human IgG antibodies, and visualization
was subsequently performed using 3 3′-diaminobenzidine
(DAB) (Vector Laboratories, Burlingame, USA).
A commercially available recombinant line assay was
used to test for antibodies against intracellular antigens:
Glutamate-Decarboxylase (GAD), Zinc-Finger Protein 4
(Zic4), Delta/Notch-like Epidermal Growth Factor-Related
Receptor (DNER), Glia-Nuclear (SOX1), Paraneoplastic
Antigen 1 (Ma1), Paraneoplastic Antigen 2 (Ma2), Amphi-
physin, Collapsin-Response-Mediator Protein 5 (CRMP5/
CV2), Purkinje cell Antigen1 (Yo), Neuronal-Nuclear
Antigen1 (HuD), Neuronal-Nuclear Antigen 2 (Ri)(ravo
PNS 11 Line Assay, ravo Diagnostika, Freiburg, Germany).
For all experiments, antibody binding was assessed by
two independent investigators on an Olympus BX61
microscope. GraphPad Prism version 5.04 was used for
statistical evaluation.
Results
Serum samples from 51 GTS patients between 18 and
64 years (age 35.0 ± 13.1 y, mean ± SD, male/female ratio
3.4:1) were investigated. Using a cell-based assay with
transfected HEK293 cells, in none of the 51 patients anti-
bodies against CASPR2 could be detected (see Fig. 1).
Using other specific cell-based assays, we found no
evidence for autoantibodies against NMDAR, AMPA1,
AMPA2, LGI1, or GABAB1/2 as well. As a screening
test for other unspecific neuronal autoantibodies, all sera
were incubated with rat tissue sections from cerebellum
and hippocampus as well as with monkey cerebellar tissue
sections. Visualization was performed either by immuno-
fluorescence or enzyme-linked using DAB to control
unspecific background staining. A specific (e.g. anti-
neuronal) binding pattern could be found in none of the
tissue sections. An anti-nuclear pattern of immunoreactiv-
ity was observed in tissue sections in 7/51 (14 %) samples.
In these 7 patients, in addition, an immunoblot analysis
was performed to investigate antibodies directed against
well-defined intracellular target antigens. Yet in none of
these patients antibodies against these diagnostically rele-
vant antigens could be detected as summarized in Table 1.
Discussion
So far, there is a controversial discussion, whether auto-
antibodies are involved in the pathophysiology of GTS.
While several studies support this “antibody hypothesis”
[12, 13], others do not [14, 15]. Substantial evidence for
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the antibody-hypothesis comes from findings demon-
strating positive CSF OCBs in 38 % of patients indicating
intrathecal immunoglobulin synthesis in GTS [3]. In
addition, morphological alterations further support this
assumption because volume increase of e.g. hippocampus
in childhood and volume reduction in adulthood resemble
inflammatory processes [16]. So far, several studies have
been performed investigating anti-streptococcal antibodies
and other specific (aldolase C, neuron-specific enolase,
non-neuronal enolase and pyruvate kinase M1) [17] and
unspecific anti-neuronal or anti-nuclear antibodies [4].
Despite the different autoantibodies of focus, some of the
discrepancies might arise from the techniques used, too.
For example, the homogenization of tissue necessary for
western blotting, might alter protein structure. On the
other hand using tissue sections with IIF a specific
intracellular antigen might not be available for antibody
binding [4] and different serum dilutions cause variable
background staining, at the expense of specificity [14].
Using live differentiated neuronal cells or transfected
cell lines most of these methodical drawbacks are miti-
gated and elevated concentrations of anti-neuronal
antibodies have been promoted to separate Sydenham
chorea from GTS [18].
In this study, we did not detect CASPR2 antibodies,
other well-defined neuronal surface antibodies or unspe-
cific anti-neuronal antibodies in sera of patients with
GTS. In tissue sections an anti-nuclear pattern of
Fig. 1 Transfected HEK cells and hippocampus sections - immunofluorescence. a transfected HEK cells expressing CASPR2, with patients serum
depicting no antibody binding, or positive CASPR2 control b, magnification 200fold IIF, scale bar 200 μm. c Tissue sections of hippocampus (rat)
with patient serum and positive CASPR2 control d, magnification 200fold, IIF, scale bar 200 μm
Table 1 Method of antibody detection and investigated target antigens
Cell based (HEK293) Tissue section Immunblot
Surface antigen Site (spezies)
Positive Total Staining
CASPR 0 51 hippocamcus (rat) IIF GAD65 Amphyphysin
Ampa 1 0 51 cerebellum (rat) IIF Zic4 CV2 (CRMP5)
Ampa 2 0 51 cerebellum (monkey) DAB Tr (DNER) Ri
LGI 1 0 51 SOX1 Yo
GABAB 1/2 0 51 Ma 2 HuD
NMDAR 0 51 Ma 1
(n = 51) (n = 7)
Transfected cells ectopically expressing (CASPR2), N-methyl-D-aspartic acid receptor (NMDAR), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
(AMPAR), Leucin-rich glioma inactivated protein (LGI1), or gamma-aminobutyric acid receptor (GABAB1/B2). Intracellular antigens: Glutamate-Decarboxylase (GAD),
Zinc-Finger-Protein4 (Zic4), Delta/Notch-like Epidermal Growth Factor-Related Receptor (DNER), Glia-Nuclear (SOX1), Paraneoplastic Antigen1 (Ma1), Paraneoplastic
Antigen2 (Ma2), Amphiphysin, Collapsin-Response Mediator -Protein 5 (CRMP5/CV2), Purkinje cell Antigen1 (Yo), Neuronal-Nuclear Antigen1 (HuD), Neuronal-
Nuclear Antigen2 (Ri)
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immunoreactivity was observed in 7 (14 %) of the 51
patients samples, which is in the range of anti-nuclear
antibodies in healthy individuals (12–16 %) [19]. In
these patients the immunoblot analysis did not reveal
any of the diagnostically relevant anti-neuronal anti-
bodies. Therefore our results do not support the hy-
pothesis that anti-neuronal antibodies in serum are an
immunopathogenic factor in GTS. This statement is
restricted by the assumption that target antigens pre-
sented solely in basal ganglia cells or cortical neurons
might have been missed.
To promote an autoantibody as immunopathogenic,
localization on target structures, disease induction after
passive transfer and remission of symptoms after with-
drawal are required conditions [20]. Diametrical results
have been found in animal experiments as some groups
were able to generate tic like symptoms in rats via anti-
neuronal antibody transfer from GTS patients [21], while
others failed to reproduce these results [22]. In order to
be able to prove pathogenicity, it is therefore desirable
to look for a specific antibody in a disease like GTS.
The appreciable frequency of CASPR2 antibody sero-
prevalence is 0.9 % in the general population [23].
Based on a known association of GTS and CNTNAP2
gene disruption which codes for CASPR2 and the role
of this antibody in the hyperexcitability in Morvan’s
disease, we used a cell-based assay to specifically look
for antibodies against this protein. The cell-based assay
provides the lowest chance of false results since on the
one hand epitope structures are unaltered and on the
other hand they are presented on the cell surface. How-
ever in sera of patients with GTS, we failed to detect
CASPR2 antibodies.
A limitation of this study is that we investigated sera,
but not CSF to detect autoantibodies in GTS. Some
autoantibodies are detected only in the CSF, but not in
serum thus, like in many other psychiatric and neuro-
logical diseases CSF investigations would be favorable
[24]. However, so far, CASPR2 positivity only in the CSF,
but not in serum has not yet been described. Particular
advantages are: 1) this is a large, prospective, and hy-
pothesis driven study, combining cell-based assays and
tissue with different detection methods and 2) frozen
serum samples were processed within one year.
In conclusion, neither serum CASPR2 antibodies nor
several other serum neuronal surface antigens such as
NMDAR play a role in the pathogenesis of GTS.
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